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Here, we show that a subset of breast cancers
express high levels of the type 2 phosphatidylino-
sitol-5-phosphate 4-kinases a and/or b (PI5P4Ka
and b) and provide evidence that these kinases are
essential for growth in the absence of p53. Knocking
down PI5P4Ka and b in a breast cancer cell line
bearing an amplification of the gene encoding
PI5P4K b and deficient for p53 impaired growth on
plastic and in xenografts. This growth phenotype
was accompanied by enhanced levels of reactive
oxygen species (ROS) leading to senescence. Mice
with homozygous deletion of both TP53 and
PIP4K2B were not viable, indicating a synthetic
lethality for loss of these two genes. Importantly
however, PIP4K2A/, PIP4K2B+/, and TP53/
mice were viable and had a dramatic reduction in
tumor formation compared to TP53/ littermates.
These results indicate that inhibitors of PI5P4Ks
could be effective in preventing or treating cancers
with mutations in TP53.
INTRODUCTION
The phosphoinositide family of lipids includes seven derivatives
of phosphatidylinositol (PI) that are formed through the phos-
phorylation of the 3-, 4-, and 5-positions on the inositol ring.
Phosphoinositides have distinct biological roles and regulate844 Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc.many cellular processes, including proliferation, survival,
glucose uptake, and migration. Phosphoinositide kinases, phos-
phatases, and phospholipases spatially and temporally regulate
the generation of the different phosphoinositide species, which
localize to different subcellular compartments. Phosphatidyli-
nositol-3,4,5-trisphosphate (PI-3,4,5-P3) is synthesized by
phosphoinositide 3-kinase (PI3K) and serves as the plasma
membrane docking site for a subset of proteins that have pleck-
strin-homology (PH) domains that bind this lipid, including the
serine/threonine protein kinase AKT (also known as protein
kinase B or PKB). AKT is a protooncogene that has critical
regulatory roles in insulin signaling and cancer progression.
Phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) is the major
substrate for class I PI3Ks and has a significant role itself in
mediating the localization of proteins to the plasma membrane
and in nucleating cortical actin polymerization (Cantley, 2002).
Until 1997, it was thought that PI-4,5-P2 was produced exclu-
sively by phosphorylation of phosphatidylinositol-4-phosphate
(PI-4-P) at the 5 position of the inositol ring, a reaction catalyzed
by the type 1 PI-4-P 5-kinases (encoded by the genes PIP5K1A,
B, and C). Unexpectedly, a second highly related family of PIP
kinases (called type 2) was found to produce PI-4,5-P2 by phos-
phorylating the 4 position of phosphatidylinositol-5-phosphate
(PI-5-P), a lipid that had been previously overlooked due to its
comigration with the much more abundant PI-4-P (Rameh and
Cantley, 1999; Rameh et al., 1997). The type 2 PIP kinases are
not present in yeast but are conserved in higher eukaryotes
from worms and flies to mammals. Humans and mice have three
distinct genes, PIP4K2A, B, and C encoding enzymes called
PI5P4Ka, b, and g, respectively. The bulk of PI-4,5-P2 in most
tissues is almost certainly derived from the type 1 PIP5Ks, yet
Figure 1. Amplification of PIP4K2B in HER-2/Neu-Positive Breast Cancers and Co-occurrence with TP53 Mutation/Deletion
(A) Genomic landscape of PIP4K2B and ERBB2 (HER2) DNA copy number amplifications in cancer. Tumor samples are divided into three groups: group I: those
with amplification in PIP4K2B but no or lower level amplification of ERBB2, group II: samples with amplification of both genes but likely to be derived from two
(legend continued on next page)
Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc. 845
recent quantitative proteomic studies on cell lines have revealed
a higher abundance of PI5P4Ks than PI4P5Ks (Nagaraj et al.,
2011). This high abundance of the type 2 enzymes may, in
part, explain why the substrate PI-5-P is present at very low
levels. Although the type 1 PIP kinases generate PI-4,5-P2 at
the plasma membrane, the type 2 kinases are located at internal
membranes, including the endoplasmic reticulum (ER), Golgi,
and nucleus and probably generate PI-4,5-P2 at those locations
(Fruman et al., 1998; Sarkes and Rameh, 2010; Schaletzky et al.,
2003; Walker et al., 2001). The vast majority of PI-4,5-P2 is
located at the plasma membrane, and it is not clear whether
the critical function of the type 2 PIP kinases is to generate
PI-4,5-P2 at intracellular sites or to maintain low levels of PI-5-
P (or both).
In a previous study, we generated mice in which one of the
type 2 PIP kinase genes (PIP4K2B) was deleted in the germline.
These mice were viable, exhibited enhanced insulin sensitivity,
and enhanced insulin-dependent activation of AKT in skeletal
muscle (Lamia et al., 2004). Paradoxically, despite increased
AKT activation the mice were smaller and had decreased
adiposity on a high-fat diet. Cell-based assays revealed that
PI5P4Kb (encoded by PIP4K2B) becomes phosphorylated by
p38 at Ser326 in response to cellular stresses, such as UV and
H2O2, and that this causes inhibition of the PI5P 4-kinase activity
and results in increased cellular PI-5-P levels (Jones et al., 2006).
These studies suggest that the type 2 PIP kinases mediate
cellular stress responses downstream of p38 (presumably by
altering the PI-5-P/PI-4,5-P2 ratio at intracellular locations) and
that under conditions of low stress, these enzymes suppress
the PI3K/AKT signaling pathway. It should be pointed out that
the type 2 PIP kinases are unlikely to supply PI-4,5-P2 as a
substrate for PI3K because activation of AKT correlates with
loss of PI5P4K activity rather than gain.
In this study, we have interrogated the potential role of type 2
PIP kinases in cancers.We found high levels of either PI5P4Ka or
PI5P4Kb enzymes or both in a number of breast cancer cell lines
and, more importantly, found amplification of the PIP4K2B gene
and high levels of both the PI5P4Ka and PI5P4Kb proteins in a
subset of human breast tumors. We found that knocking down
the levels of both PI5P4Ka and PI5P4Kb in a TP53-deficientdifferent amplicons, and group III: samples with amplification in both genes der
gain (red).
(B) Oncoprints of PIP4K2B and TP53 across 66 breast carcinomas indicating a tre
deletion (p value: 0.006306, Fisher’s exact test). Individual genes are represented
alterations are color-coded with red indicating amplification; pink, DNA copy num
cases with gain/amplification of PIP4K2B are included. These oncoprints are base
org/su2c-portal/).
(C) Box plots indicating that the levels of ERBB2 phosphorylation on tyrosine 12
higher in breast carcinomas with PIP4K2B gain/amplification (p value: 1.7 3 10
(D) Box plots indicating that the levels of AKT phosphorylation on threonine 308 (T
PIP4K2B gain/amplification (p value: 0.007), whereas the total AKT levels remain u
(http://cbio.mskcc.org/su2c-portal/).
(E) Upper: box plots indicating the expression of TP53 (blue) and PIP4K2A (red) ac
number status of TP53. (Homdel: homozygous deletion [n = 0], Hetloss: heteroz
as expected progressively higher across the different subgroups of breast carcino
4.33 106), whereas PIP4K2A expression is only significantly higher in the subgro
p = 0.009). Lower: box plots indicating the expression of PIP4K2B (orange) and P
putative DNA copy number status of TP53. The expression of either PIP4K2B or P
with different ploidy status of TP53 (one-way ANOVA, p > 0.05).
846 Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc.breast cancer cell line blocked growth on plastic and in xeno-
grafts. This impaired growth correlated with impaired glucose
metabolism and enhanced levels of reactive oxygen species
(ROS) leading to senescence. The impaired glucosemetabolism,
despite activation of the PI3K-AKT pathway (which typically
enhances glucose metabolism) was paradoxical. The results
indicate that PI3K activation is not driving the ROS production
but may be an inadequate feedback attempt to restore glucose
uptake and metabolism.
Finally, to assess the role of type 2 PIP kinases in tumor forma-
tion, we generated mice with germline deletions of PIP4K2A and
PIP4K2B and crossed these with TP53/ mice and evaluated
tumor formation in all the viable genotypes. We found that
mice with homozygous deletion of both TP53 and PIP4K2B
were not viable, indicating a synthetic lethality for loss of these
two genes. Importantly, mice with the genotype PIP4K2A/,
PIP4KB+/, TP53/ were viable and had a dramatic reduction
in tumor formation compared to siblings that were TP53/
and wild-type for PIP4K2B and/or PIP4K2A genes. These results
suggest that PI5P4Ka and PI5P4Kb could be targets for pharma-
ceutical intervention in cancers that are defective in TP53.
RESULTS
Amplification of PIP4K2B in HER-2/Neu-Positive Breast
Cancers and Co-Occurrence with TP53 Mutation/
Deletion
Gene amplification in breast cancer is associated with disease
progression, adverse prognosis, and development of drug resis-
tance. PIP4K2B is located in a chromosomal region (17q12)
close to ERBB2 (HER2/Neu), which is amplified in about 25%
of breast cancers and in a smaller fraction of nonsmall cell lung
adenocarcinomas, as well as other cancer types including colo-
rectal and renal (Luoh et al., 2004; Slamon, 1987; Slamon et al.,
1989, 2001). Approximately half of the breast tumors that exhibit
ERBB2 amplification also exhibit amplification of PIP4K2B (Fig-
ure 1A). For the majority of tumors that have both ERBB2 and
PIP4K2B amplified, the two genes are on the same amplicon
(Figure 1B). However, for a significant fraction (27/78) these
two genes appear to be on distinct amplicons. Also, tumorsived from the same amplicon. Colored bar indicates degree of copy number
nd of co-occurrence between PIP4K2B gain/amplification and TP53 mutation/
as rows, and individual cases or patients are represented as columns. Genetic
ber gain; light blue, hemizygous deletion and green box, point mutation. Only
d on data obtained from the Stand Up to Cancer cBio portal (http://cbio.mskcc.
48 (y1248) (left) and of total ERBB2 (right) measured by RPPA are significantly
5, p value: 4.2 3 106, respectively).
308) (left) measured by RPPA are significantly lower in breast carcinomas with
nchanged (p value: 0.24) Data obtained from the StandUp toCancer cBio portal
ross different subsets of breast carcinomas divided by the putative DNA copy
ygous deletion (n = 1), diploid: n = 2, gain: n R 3). TP53 mRNA expression is
mas with TP53 ploidy status ranging from n = 0 to nR 3 (one-way ANOVA, p =
up of breast carcinomas with homozygous deletion of TP53 (one-way ANOVA,
IP4K2C (yellow) across different subsets of breast carcinomas divided by the
IP4K2C is not significantly different across the subgroups of breast carcinomas
Figure 2. PI5P4K Expression in Breast Cancer
(A) Histograms illustrating expression levels of
PI5P4Ka (***p = 0.000) or PI5P4Kb (**p = 0.004) in
breast cancer samples.
(B) Representative IHC images from breast tumor and
normal samples. Scale bar, 100 mm.
(C) PI5P4Ka and PI5P4Kb expression in panel of
breast cancer cell lines.
See also Figure S1 and Tables S1 and S2.were identified that had relatively focal amplification of PIP4K2B
without amplification of ERBB2 (Figure 1A). Amplification of
PIP4K2Awas only observed in a small fraction of breast cancers
(data not shown). Furthermore, it is interesting to note that the
genomic alteration of PIP4K2B and TP53 across 66 breast carci-
nomas indicate a trend of co-occurrence between PIP4K2B
gain/amplification and TP53 mutation/deletion (Figure 1B).
Interestingly, using reverse phase protein array (RPPA) a high-
throughput proteomics technology we could correlate PIP4K2B
gain/amplification with a significant increase in ERBB2 phos-
phorylation on tyrosine 1248 (Y1248) and of total ERBB2 levels
(Figure 1C), as well as, with a small but significant decrease in
the phosphorylation of AKT on threonine 308 (T308) with no
change in total AKT protein levels (Figure 1D). To further address
the link between PIP4K2A/B and TP53 in cancers, we more
deeply interrogated the rapidly growing TCGA database ofCell 155, 844–85breast cancers. We found that the subgroup
of breast cancers that had homozygous
deletion of TP53 (analogous to the TP53-
null mouse breast cancers discussed
below) had significantly higher PIP4K2A
mRNA compared to tumors with two alleles
of TP53 or heterozygous loss of TP53 (Fig-
ure 1E). There was also a trend toward
higher expression of PIP4K2B and PIP4K2C
in the tumors with homozygous deletion of
TP53 (Figure 1E), though these changes
did not reach significance.
PI5P4K Expression in Breast Cancer
To evaluate PI5P4Ka and b protein levels
in breast cancer, we utilized antibodies
against these proteins for immunohisto-
chemistry staining of a breast cancer tissue
array (Figures 2A, 2B, and S1 available
online; Tables S1 and S2). As shown in Fig-
ure 2, PI5P4Ka expression is detectable
in both normal breast and breast cancer,
but high levels of expression are found in
74% of tumors and only 29% of normal
breast epithelium. This high level of expres-
sion is distributed over all the major
subtypes. In contrast, PI5P4Kb was not
detected in any of the normal breast
epithelial tissue but was highly expressed
in 38% of the breast tumors. The subset
of tumors with the highest level of expres-sion was the HER2-positive group where 62% had high levels
of PI5P4Kb. Thus, the HER2 subtype has high protein expres-
sion, consistent with a high frequency of PI5P4Kb gene ampli-
fication (Figure 1A).
We also evaluated the total protein expression of both iso-
forms in a panel of breast cancer cell lines using western blots.
PI5P4Ka is expressed in all the breast cancer cell lines that we
investigated, whereas PI5P4Kb is expressed at very low levels
in most breast cancer cell lines, with the exception of BT474
cells, which have both ERBB2 and PIP4K2B amplified (14 and
12 alleles, respectively) (https://cansar.icr.ac.uk/cansar/). Inter-
estingly, the T47D cell line has four alleles of PIP4K2B and also
shows some increased expression (Figure 2C). In contrast,
AU565 cells have ERBB2 amplified but have only two alleles
of PIP4K2B and do not express high levels of this protein
(Figure 2C).7, November 7, 2013 ª2013 Elsevier Inc. 847
(legend on next page)
848 Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc.
Knockdown of Both PI5P4Ka and b in BT474 Cells
Abrogates Cell Proliferation and Impairs Tumor Growth
in a Xenograft Model
Because BT474 cells exhibit amplification of the PIP4K2B gene
and express high levels of the protein encoded by this gene
(PI5P4Kb), we examined the effect of knocking down expression
of either this gene alone or both PIP4K2B and PIP4K2A on cell
growth. Knocking down expression of either gene alone with
small hairpin RNA (shRNA) had little effect on cell growth (Figures
3 and S2; Table S3), but knocking down expression of both
genes caused a dramatic inhibition of cell growth (Figure 3).
Two independent sets of shRNAs targeting these proteins
resulted in effective decreases in both PI5P4Ka and b (Figures
3A and 3B) and resulted in approximately 80% reduction in
cell number over a 72 hr period of cell growth (Figure 3C). Impor-
tantly, to address any off target effects of the hairpins, we
rescued cell proliferation of the double-knockdown line by
expressing a flag-tagged version ofmouse PI5P4Kb that circum-
vents the shRNA directed against human PI5P4Kb (Figures 3D
and 3E).
To address whether loss of p53 function contributes to the
impaired growth of BT474 cells in the context of PI5P4Ka and
b knockdown, we took advantage of the previous observation
that the p53 E285K mutation in these cells is nonfunctional at
37C but functional at 32C (Dearth et al., 2007). Consistent
with the previous publication, p53 activity was at least partially
restored when BT474 cells were cultured at 32 degrees, as
assessed by increased expression of the p53 target gene p21.
Importantly, the shift to 32C resulted in a partial rescue of
proliferation (Figure 3F). As expected, the control pLKO.1
BT474 cells grew somewhat slower when shifted to 32C. These
results are consistent with a model in which knocking down
PI5P4Ka and b only impairs cell growth when p53 is defective.
We also found that knocking down both PI5P4Ka and b in
BT474 cells dramatically impaired tumor formation in xenografts
(Figures 3G and 3H). The striking differences in tumor formation
in the xenografts were due to a dramatic decrease in viable cells
in the PI5P4Ka/b knockdown xenograft tumors compared to theFigure 3. Knockdown of Both PI5P4Ka and b in BT474 Cells Abrogate
(A and B) Stable knockdown of PI5P4Ka/b in BT474 cells. shPI5P4ka/b-1 (seque
against PI5P4ka and PI5P4kb. All single knockdowns are sequence 1 (see Expe
(C) Luminescent cell viability assay in stable PI5P4Ka/b knockdown cells. Resu
value ± SEM. ***p value < 0.0001 with two-tailed Student’s t test.
(D) Stable overexpression of mouse Flag-tagged PI5P4Kb in BT474 cells and su
(E) Mouse Flag-tagged PI5P4Kb rescues proliferation in PI5P4Ka/b knockdown ce
mean value ± SEM.
(F) Right: Luminescent cell viability assay in stable PI5P4Ka/b knockdown cells c
points. Results are from three independent experiments and are represented as th
levels in BT474 cells cultured at restrictive and permissive conditions for 24 hr.
(G) Tumor formation over time in nude mice injected with the BT474 cancer cell lin
(H) Images of tumors, pLK0.1 control cells (left flank), or shPI5P4Ka/b (right flank
(I) Histogram showing percentages of viable area in PI5P4Ka/b knockdown and co
displayed as means ± SD.
(J) Histogram displaying expression levels of Ki67-positive cells in shPI5P4Ka/b a
pLK0.1 xenografts. Data from two independent experiments were considered an
(K) Upper: histogram illustrating expression levels of p27-positive cells in shPI5P4
b and pLK0.1 xenografts. Data from two independent experiments were considere
p27 immunostains are shown. Scale bar, 100 mm.
See also Figure S2 and Table S3.BT474 vector control xenograft tumors (Figure 3I), along with a
slight decrease in Ki67 staining (Figure 3J). Most strikingly
though is the strong increase in p27 (a marker of senescence)
(Young and Kaelin, 2008; Young et al., 2008) in the PI5P4K a/b
knockdown xenograft tumors compared to the BT474 vector
control xenograft tumors (Figure 3K). These results support a
model in which the loss on PI5P4K leads to a cell-cycle-arrest
phenotype in vitro and a nonviable tumor in vivo. Furthermore,
these data imply that the knockdown of PI5P4K in vivo may
lead to senescence.
Knockdown of Both PI5P4Ka and b in BT474 Cells
Enhances PI3K Signaling, Increases ROS and
Respiration, and Triggers Senescence
Consistent with our previous observation of increased in vivo
AKT activity in response to deletion of the PIP4K2B gene in
mice (Lamia et al., 2004), the knockdown of both PI5P4Ka
and b resulted in increased basal AKT phosphorylation in
BT474 cells (Figures 4A and S3). This increase in AKT phos-
phorylation could be explained by an increase in PI-3,4,5-P3
levels in response to knockdown of both PI5P4Ka and b (Fig-
ure 4C). Surprisingly, we observed a dramatic decrease in
PI-3,4-P2 in the double-knockdown cells (Figure 4C). PI-3,4-P2
can be degraded to PI-3-P by the phosphatase, inositol
polyphosphate 4-phosphatase-IIB (INPP4B) (Gewinner et al.,
2009; Norris et al., 1995, 1997) so we investigated the level of
this enzyme in the BT474 cells. The levels of INPP4B were virtu-
ally undetectable in BT474 cells prior to the knockdown of
PI5P4Ka and b but were quite high following the knockdown,
explaining the drop in PI-3,4-P2 levels (Figures 4B and 4C).
These results suggest a negative feedback loop in which
INPP4B upregulation is an attempt to suppress PI-3,4-P2 acti-
vation of AKT (Franke et al., 1997; Gewinner et al., 2009). We
detected no significant change in PI-4,5-P2 levels, indicating
that the majority of PI-4,5-P2 is produced by type 1 PIP kinases,
as previously assumed (Figure 4C).
The increase in PI3K/AKT signaling, yet decrease in cell pro-
liferation in response to knockdown of both PI5P4Ka and b,s Cell Proliferation and Fail to Form Tumors in Xenograft Model
nce 1) and shPI5P4ka/b-2 (sequence 2) are two independent hairpins targeted
rimental Procedures).
lts are from four independent experiments and are represented as the mean
bsequent stable PI5P4Ka/b knockdown.
lls. Results are from three independent experiments and are represented as the
ultured at restrictive (37C) and permissive conditions (32C) for indicated time
emean value ± SEM. Left: Total p53, p21, and GAPDH (loading control) protein
e expressing shRNA pLK0.1 control or shRNA PI5P4K a/b. Error bars are SEM.
) after mice were euthanized.
ntrol xenografts. Data from two independent experiments were considered and
nd pLK0.1 xenografts. Quantification of Ki67-positive cells in shPI5P4Ka/b and
d displayed as means ± SD.
Ka/b and pLK0.1 xenografts. Quantification of p27-positive cells in shPI5P4Ka/
d and displayed asmeans ± SD (***p < 0.001). Lower: representative images of
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Figure 4. Knockdown of Both PI5P4Ka and b in BT474 Cells Enhances PI3K Signaling, Increases ROS and Respiration, and Triggers
Senescence
(A) AKT phosphorylation at serine 473(pS473) and total AKT protein levels in pLK0.1 vector control cells and in shPI5P4ka/b double-knockdown cells. Cells were
serum starved overnight and then treated with media with 10% serum for the indicated time points.
(legend continued on next page)
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seems paradoxical given the established role of PI3K as an
oncogene and in promoting cell growth and cell survival. The
decrease in cell number was not due to an increased rate of
cell death as judged by no change in LDH release from the cells
(Figure 4D). However, we observed a significant increase in reac-
tive oxygen species (ROS), in oxygen consumption, and in
b-galactosidase staining in the BT474 cells in response to knock-
down of both PI5P4Ka and b consistent with ROS-induced
senescence (Figures 4E–4G).
Hyperactivation of the PI3K/AKT pathway due to loss of
PTEN (and INPP4B) has previously been shown to induce
senescence (Chen et al., 2005; Gewinner et al., 2009; Nogueira
et al., 2008), raising the possibility that activation of AKT in
response to PI5P4Ka/b knockdown is responsible for the
senescence that we observed in the BT474 cells. However,
BT474 cells are defective in p53, which typically mediates
PI3K/AKT pathway-dependent senescence. To evaluate the
possibility that the ROS and senescence observed in response
to knockdown of PI5P4Ka/b is a consequence of PI3K/AKT
activation, we treated these cells with the pan-PI3K inhibitor
GDC-0941 to block this pathway (Figure S3). Rather than
restoring growth in the PI5P4Ka/b knockdown BT474 cells,
GDC-0941 caused a decrease in cell number (Figure 4I).
GDC-0941 caused a small elevation in ROS in control BT474
cells and did not lower ROS levels in PI5P4Ka/b knockdown
BT474 cells (Figure 4H). These data indicate that the ROS and
senescence observed in PI5P4Ka/b knockdown cells is not
due to activation of the PI3K/AKT pathway and raise the possi-
bility that activation of this pathway is an attempt to rescue the
cells from ROS.
In contrast to the results with BT474 cells, knocking down
PI5P4Ka and b in a breast cancer cell line (MCF7 cells) that
does not have PIP4K2B amplified or overexpressed and has
wild-type p53 and an activatingmutation in PIK3CA had no effect
on growth or AKT signaling (Figure S2). Together, these data
suggest that maintaining high levels of PI5P4Ka and b, in part
through amplification of the PIP4K2B gene, is critical to prevent
senescence in specific mutational backgrounds (e.g., HER2
amplification and p53 loss) but is not, in general, essential for
the growth of cancer cell lines.(B) Total INPP4B protein levels in pLK0.1 vector control cells and in shPI5P4ka/b d
expression of INPP4B.
(C) BT474 pLK0.1 control vector cells or PI5P4Ka/b knockdown cells labeled with
normalized to PI4P levels. Results are from three independent experiments and
t test.
(D) Cell death of pLK0.1 control or shRNA PI5P4K a/b double-knockdown cells
experiments are shown.
(E) ROS determined by incubating pLK0.1 control or shRNA PI5P4K a/b double-kn
15 min as positive control. n = 4 mean ± SEM. **p < 0.001 with two-tailed Stude
(F) Oxygen consumption of pLK0.1 control or shRNA PI5P4K a/b double-knockd
(G) pLK0.1 control or shRNA PI5P4K a/b double-knockdown cells were plated
performed in triplicate.
(H) ROS determined by incubating pLK0.1 control or shRNA PI5P4K a/b double-k
with GDC-0941 (1 mM) or N-acetylcysteine (NAC) (10 mM) for 24 hr. n = 3 mean
(I) Luminescent cell viability assay in stable (upper) pLK0.1 control cells and (lower
time points. Results are from three independent experiments and are represente
(J) Immunohistochemical detection of 8-oxo-dGuo in pLK0.1 and shPI5P4Ka/b xe
(mouse #6 and mouse #10). Scale bar,100 mm.
See also Figure S3.Altered Gene Expression and Metabolomic Signatures
in the PI5P4Ka/b Double-Knockdown BT474 Cells
To further explore the phenotype of knocking down PI5P4Ka
and b in BT474 cells, we performed a microarray analysis. As
illustrated in the heatmap, there are striking differences in gene
expression between the control and PI5P4Ka/b knockdown cells
(Figure S4; Table S4), particularly in relation to genes involved in
the p38MAPK pathway (Figure 5A). Consistent with this, we also
observe an increase in phospho-p38 MAPK in the PI5P4Ka/b
knockdown cells (Figure S3). These microarray results support
the idea that PI5P4Ka and b regulate cellular stress responses
in the p38MAPK pathway and corroborate previous studies indi-
cating that p38 MAPK modulates PI-5-P levels by phosphory-
lating PI5P4Kb (Jones et al., 2006). We next performed gene
set enrichment analysis (GSEA) to show that the PI5P4Ka/b
double-knockdown cells are significantly enriched in the luminal
compared to the basal or mesenchymal-type gene expression
signature (Figure 5B). We also performed gene ontology analysis
of the microarray data between the control versus shPI5P4Ka/b
double-knockdown cells to show that the most differentially
expressed hits are genes that control the rate and direction of
cellular metabolism (Figure S5; Table S5).
To better understand the effect of knocking downPI5P4Ka and
boncellularmetabolism inBT474cells,weutilized targetedmass
spectrometry to examine the level of 180metabolites.We founda
significant drop in intermediates in glucose metabolism in the
PI5P4Ka/b knockdown cells (Figure S5; Table S5). These results
are paradoxical. In most cellular contexts, an increase in PI3K/
AKT signaling results in increased glycolysis and decreased
oxidative phosphorylation (theWarburg effect), but in the context
of PI5P4Ka/b knockdown in BT474 cells PI3K/AKT signaling is
increasedbut glucosemetabolism is decreasedandoxygencon-
sumption is increased (reversal ofWarburg effect). The increased
oxygen consumption (presumably due to increased oxidative
phosphorylation to maintain ATP levels at low rates of glycolysis)
could explain the higher ROS levels (Figures 4E, 4F, and 4H). The
metabolic imbalance and consequent high ROS levels are likely
to contribute to the senescence observed.
In contrast to the effects seen in BT474 cells, knocking down
PI5P4Ka/b in MCF7 cells did not cause a decrease in glucoseouble-knockdown cells. TheMCF7 breast cancer cell line is known to have high
[3H]-inositol for 48 hr. Deacylated lipids were analyzed byHPLC, quantified, and
are represented as the mean value ± SEM. *p < 0.01 with two-tailed Student’s
was assessed by LDH release. Mean values ± SEMs from four independent
ockdown cells with DCFH-DA (10 mM) for 30min or a bolus of H2O2 (100 mM) for
nt’s t test.
own cells. n = 4 mean ± SEM. **p < 0.001 with two-tailed Student’s t test.
for senescence assay. Images presented from a representative experiment
nockdown cells with DCFH-DA (10 mM) for 1 hr. Cells were untreated or treated
± SEM. **p < 0.001 with two-tailed Student’s t test.
) PI5P4Ka/b knockdown cells ±GDC-0941 (1 mM) or NAC (10mM) for indicated
d as the mean value ± SEM.
nografts. Two representative images of 8-oxo-dGuo immunostains are shown
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Figure 5. Distinct Gene Expression and Metabolomic Signatures in
the PI5P4Ka/b Double-Knockdown Cells
Expression data of PI5P4Ka/b knockdown cells (shPI5P4Ka/b) or control vector
cells (pLK0.1) using Affymetrix Human Genome U133 Plus (40,000 genes).
(A) Enrichment analysis of the curated pathways (BioCarta) following PI5P4Ka/b
knockdown. The p38MAPK and RAS signaling pathways were identified as the
most significant pathways with respective p values of 1.833 104 and 0.004.
(B) Gene set enrichment analysis (GSEA) signatures highlighting coordi-
nated differential expression of gene sets that are enriched in PI5P4Ka/b
knockdown cells. The CHARAFE_BREAST_CANCER_LUMINAL _VS_
MESENCHYMAL_UP (genes upregulated in luminal-like breast cancer
cell lines compared to the mesenchymal-like ones) and CHARAFE_
BREAST_CANCER_ LUMINAL_VS_BASAL_UP (genes upregulated in luminal-
like breast cancer cell lines compared to the basal-like ones) were scored
among the most significantly enriched gene signatures in PI5P4K knockdown
cells, p < 0.001.
See also Figures S4 and S5 and Tables S4 and S5.
852 Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc.metabolites (Figure S2; Table S3). These data suggest that it
is the decreased glucose metabolism, unique to BT474 cells,
that causes ROS and senescence in these cells. To further
interrogate whether the ROS is responsible for the decrease in
the growth of PI5P4Ka/b knockdown BT474 cells, we added
the antioxidant N-acetylcysteine (NAC) to the media and found
that this partially rescued the cell growth (Figure 4I). Consistent
with the in vitro data, the PI5P4Ka/b knockdown xenograft
tumors have higher levels of 8-hydroxydeoxyguanosine
(8-oxodGuo), an indicator of ROS-dependent DNA damage,
than the control BT474 tumors, indicating that oxidative stress
is higher in the PI5P4Ka/b knockdown tumors (Figure 4J).
The strong correlation between high expression of PI5P4Ka or
b in human breast cancers that lack both alleles of p53 and the
observation that knocking down PI5P4Ka/b in a cell line that
lacks p53 (BT474) results in senescence, whereas knocking
down these genes in a cell line with wild-type p53 (MCF7) had
no effect raises the possibility that expression of PI5P4Ka/b
genes may only be essential under conditions of stress and
that they may be particularly important for growth of cancers
that lack p53. To explore this possibility, we generated mice
with genetic deletions of PIP4K2A and crossed them into
PIP4K2B/ and TP53/ backgrounds.
PIP4K2A/ Mice Are Viable and Appear Normal
We generated mice deficient for PIP4K2A, using a conditional
targeting strategy (Figure 6A). Clones were picked and analyzed
for homologous recombination into the endogenous PIP4K2A
locus using a combination of Southern blot (Figure 6B) and
PCR analysis (Figure 6C). A representative NdeI digest, followed
by Southern blot analysis of one positive and one negative
neomycin resistant clone, is shown using the indicated E3 probe
(Figures 6A and 6B). A representative PCR using three mice is
seen in Figure 6C, indicating the expected products from germ-
line deleted PIP4K2A/, PIP4K2A+/, and PIP4K2A+/+ mice.
Western blot analysis of brain tissue from PIP4K2A/ mice us-
ing an antibody that recognizes both PI5P4Ka and b indicated
that the gene product PI5P4Ka was not detected after germ-
line deletion, nor were any truncated proteins (Figure 6D).
PIP4K2A/ mice were born in near Mendelian ratios and dis-
played no obvious histological, growth, or reproductive pheno-
types (data not shown). Also, in contrast to PIP4K2B/ mice
Figure 6. Requirement for PIP4K2A and
PIP4K2B for Survival and Growth
(A) Schematic representation of wild-type
PIP4K2A locus, targeting vector, recombined
allele and FlpR/CreR-deleted null allele. Neomycin
resistance cassette flanked by Frt sites (yellow
boxes), exon 2 flanked by loxP sites (red arrows),
and diphtheria toxin cassette located 30 to exon 2.
N, NdeI restriction site.
(B) Southern blot of embryonic stem cell clones
(wild-type and targeted) using probe E3 after NdeI
digestion.
(C) PCR analysis of genomic DNA derived from
PIP4K2A F2 littermates.
(D) PI5P4Ka and b protein levels from brain
homogenate of PIP4K2A F2 littermates.
(E) PI5P4Ka and b protein levels in primary MEFs
derived from intercrossing PIP4K2A and PIP4K2B
knockout mice.
(F) Genotyping results of PIP4K2A/2B double
heterozygote interbreeding at weaning (observed
numbers in bold, expected in parentheses).
(G) Body weight (in grams) measurements of
indicated mouse genotypes. Results represented
as the mean value ± SEM. ***p < 0.0001 with two-
tailed Student’s t test.
(H) Quantitation of PI5P levels in PIP4K2A/2B-
deficient relative to PIP4K2A/2B heterozygous
MEFs. Results are from three independent
experiments and are represented as the mean
value ± SEM.
See also Figure S6.that are growth retardedwith decreased adiposity and increased
insulin sensitivity (Lamia et al., 2004), PIP4K2A/mice were like
wild-type littermates in regard to all these characteristics (data
not shown).
PIP4K2A/ PIP4K2B/ Mice Develop Normally, but
Exhibit Neonatal Lethality
The absence of a significant phenotype for the PIP4K2A/mice
led us to breed these mice to the PIP4K2B/ mice in order
to generate PIP4K2A/, PIP4K2B/ mice. The cross and
backcross of PIP4K2A+/ mice to PIP4K2B+/ mice resulted inCell 155, 844–857,non-Mendelian ratios of offspring (Fig-
ure 6F). Most notably, no pups of the
PIP4K2A/ PIP4K2B/ genotype were
viable: these pups looked normal at birth
and were able to suckle but died within
12 hr. Therewas also a sub-Mendelian ra-
tio of viable mice of the PIP4K2A+/,
PIP4K2B/ genotype (19 out of 43
expected). Thesemice were born atMen-
delian ratios with normal appearance and
weight, but approximately half died within
12 hr. The survivors were growth retarded
with only 50% the weight of wild-type lit-
termates at the adult stage (Figure 6G). All
other genotypes appeared at Mendelian
ratios. No histological abnormalitieswere observed in any of the genotypes. These observations indi-
cate that type II PI5P4Ka and b are not essential for normal em-
bryonic development but are critical for surviving the stresses of
birth and contribute to growth following birth. Consistent with
normal embryonic development, PIP4K2A/ PIP4K2B/
mouse embryonic fibroblasts (MEFs) grow at a normal rate
(data not shown). Also, consistent with enhanced PI3K/AKT
signaling in the PI5P4Ka/b knockdown BT474 cell lines (above)
and in muscle from PIP4K2B/ mice (Lamia et al., 2004), intro-
duction of cre recombinase toPIP4K2Aflx/PIP4K2B/MEFs to
delete the second allele of PIP4K2A resulted in prolonged AKTNovember 7, 2013 ª2013 Elsevier Inc. 853
Figure 7. PI5P4K Deficiency Restricts Tumor Death after p53
Deletion
Kaplan-Meier plot analysis of tumor free survival (15 PI5P4Ka+/+ PI5P4Kb+/+
and 20 PI5P4Ka/PI5P4Kb+/). *p < 0.05 with two-tailed Student’s t test. See
also Figure S7.phosphorylation at Thr308 (Figure S6). Conversely, overexpress-
ing PIP4K2A in the same background suppresses Thr308 phos-
phorylation (Figure S6). Consistent with PI-5-P being the
substrate of the PI5P4Ks, the PIP4K2A/, PIP4K2B/ MEFs
had higher levels of PI-5-P than the PIP4K2A+/, PIP4K2B+/
MEFs derived from littermates (Figure 6H). In contrast to the
BT474 cells where knockdown of these genes caused senes-
cence, no senescence was observed in the PIP4K2A/,
PIP4K2B/ MEFs.
PI5P4K Deficiency Reduces Tumor-Dependent Death in
TP53/ Mice
Previous studies have indicated a major role for p53 in mediating
cellular responses to stress, especiallymetabolic stress and ROS
stress (Vurusaneret al., 2012).Ourobservationof increasedmeta-
bolic stress andROS, leading to senescence upon knockdown of
PI5P4Kaandb in a cell line lackingp53 (BT474) but no inductionof
senescence in MEFs in the context of deletion of PIP4K2A
and PIP4K2B, raised the possibility that partial loss of PIP4K2A
and/or PIP4K2B alleles, although viable in normal tissues, may
result in senescence in the context of p53-deleted tumors. To
test this idea, we crossed the PIP4K2A/, PIP4K2B+/ mice
with TP53/mice andmonitored tumor formation in all the viable
mice that emerged from the backcrosses. In approximately
4–6 months, mice deficient in p53 develop spontaneous tumors,
with the majority being lymphomas and soft tissue sarcomas
(Jacks et al., 1994). In contrast, we find that PIP4K2A/,
PIP4K2B+/, TP53/ mice that emerged from the crosses
had a dramatic reduction in tumors compared to PIP4K2A+/+,
PIP4K2B+/+, TP53/ mice (Figures 7 and S7).
Deletion of PIP4K2B and TP53 Results in Synthetic
Lethality
Although PIP4K2B/ mice are viable and appear at Mendelian
ratios and have a normal lifespan in TP53wild-type backgrounds
(Lamia et al., 2004), no mice with the PIP4K2B/, TP53/ ge-
notype emerged from the crosses, indicating synthetic lethality854 Cell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc.upon loss of TP53 and PIP4K2B. In order to investigate why
PIP4K2B/, TP53/mice are not viable we set up timedmating
pairs and at E12.5, we were able to get one double-knockout
embryo out of 11 from three litters. Deletion of both alleles of
the PIP4K2B and TP53 genes caused exencephaly (data not
shown), a failure of neural tube closure that is occasionally
observed in TP53/ mice, but that does not usually cause early
embryonic lethality (Jacks et al., 1994). In contrast, loss of only
one allele of PIP4K2B and both alleles of PIP4K2A in the context
of p53 deficiency results in viable mice but an apparent synthetic
lethality for the TP53/ tumors.
DISCUSSION
Here, we have shown that the PIP4K2B gene is amplified in a
subset of tumors, especially in HER2-positive breast tumors,
and that, although this gene is often in the same amplicon with
ERBB2, in many tumors it is in a separate amplicon, and in
some tumors it is amplified independent of ERBB2 amplification.
Importantly, we have found that the protein product of this gene,
PI5P4Kb, is highly expressed in a majority of HER2-positive
tumors. The related enzyme, PI5P4Ka, which ismore broadly ex-
pressed, was also found to be elevated in many breast tumors.
We showed that BT474 cells, which exhibit amplification of
both ERBB2 and PIP4K2B and loss of p53, express high levels
of both PI5P4Ka and b and that knocking down the expres-
sion of these proteins results in impaired glucose metabolism,
increased ROS, and senescence.While this paper was in review,
Jones et al. (2013) was published, demonstrating that addition of
peroxide to cells increases PI-5-P levels (especially in cells lack-
ing p53). Furthermore, overexpression of PI5P4Ka prevented the
elevation in PI-5-P and also rescued cell growth in the presence
of ROS providing independent evidence of a role for PI5P4Ks in
rescuing cells from ROS toxicity.
The biochemical mechanism by which PI5P4Ks protect from
ROS in the context of p53 deletion is not clear. Our studies sug-
gest that high levels of PI5P4Ks are required to maintain high
rates of glucosemetabolism, thereby reducing rates of ROS pro-
duction from oxidative phosphorylation and enhancing NADPH
production via the pentose phosphate pathway. The role of
PI5P4Ks in maintaining glucose metabolism appears to only be
critical in the context of p53 loss. Cell lines (e.g., MCF7 cells
and MEFs) with wild-type p53 do not show defects in glucose
metabolism, enhanced ROS, or senescence upon loss of
PI5P4Ks, and muscle tissue shows enhanced glucose uptake
upon loss of PI5P4Kb (Lamia et al., 2004). These results suggest
that, in the absence of PI5P4Ks, p53 mediates an adaptive
response to ROS, by maintaining glucose uptake and flux into
the pentose phosphate pathway. Indeed, several studies have
indicated an important role for p53 in maintaining glucose and
ROS homeostasis, in part via TIGAR (Mor et al., 2011). Our
studies support this concept and argue that when both p53
and PI5P4Ks are absent cells are not capable of maintaining
glucose and ROS homeostasis. Interestingly, some recent
studies also indicate a role for p53 in enhancing ROS in some
mutational backgrounds (for review, see Vurusaner et al., 2012).
Jones et al. (2013) have proposed that the critical role of
PI5P4Ks is to suppress the high levels of PI-5-P that appear in
response to ROS, implying that PI-5-P is a second messenger
that mediates or enhances ROS-dependent cell damage. An
alternative possibility, consistent with the data presented in this
article, is that PI5P4Ks, when presented with high levels of PI-
5-P (due to ROS), generate PI-4,5-P2 at an intracellular location
that facilitates cellular responses that enhance glucose meta-
bolism and suppress ROS.
The fact that knocking down PI5P4Ks both activates the PI3K/
AKT pathway and suppresses glucose metabolism (in p53-defi-
cient BT474 cells) is paradoxical. In other contexts, activation of
the PI3K/AKT pathway enhances glucose uptake and meta-
bolism, and, in the context of wild-type p53, deletion of PIP4K2B
in mice activates the PI3K/AKT pathway and enhances glucose
uptake into muscle (Lamia et al., 2004). The data presented here,
using the pan PI3K inhibitor GDC0941, show that the activation
of the PI3K/AKT pathway is not responsible for the ROS and
senescence in BT474 cells. It is likely that the PI5P4Ks suppress
PI3K/AKT signaling because they provide an alternative mecha-
nism for enhancing glucosemetabolism in response to ROS. The
activation of PI3K/AKT signaling upon suppressing PI5P4Ks is
clearly not sufficient to restore glucose and ROS homeostasis
when p53 is not present.
The decreased tumor incidence in the background of
PIP4K2A/, PIP4K2B+/, TP53/ compared to TP53/ alone
is particularly interesting with respect to Li-Fraumeni syndrome
(germline TP53 mutations). Our results indicate that expression
of PI5P4Ka and/or b is critical for the growth of tumors with
TP53 mutations or deletions. Thus, coamplification of PIP4K2B
with ERBB2 might explain why breast cancers in patients with
Li-Fraumeni syndrome show ERBB2 amplifications (HER2 posi-
tive) in over 83% of cases as opposed to 16% of age-matched
patients with wild-type TP53 (Wilson et al., 2010).
The results that we present here suggest that PI5P4Ka and b
play a critical role in mediating changes in metabolism in
response to stress, and, in particular, ROS stress that occurs
in the absence of p53. Germline deletion of either PIP4K2A or
PIP4K2B alone resulted inmice with normal lifespans, and germ-
line deletion of both PIP4K2A and PIP4K2B resulted in full-term
embryos of normal size and appearance at birth, indicating that
these genes do not play a major role in normal embryonic growth
and development. Yet, the PIP4K2A/, PIP4K2B/ pups die
shortly after birth, consistent with these genes having a role in
mediating stress responses known to occur following birth.
Importantly, germline deletion of both PIP4K2B and TP53
resulted in lethality, whereas germline deletion of either gene
alone resulted in Mendelian ratios of viable pups. Thus, the
genetic studies suggest that TP53 and PIP4K2B have overlap-
ping roles in mediating cellular responses to stress and that,
whereas neither gene alone is essential, loss of both genes is
not tolerated.
The most exciting observation from these studies in regard to
potential new therapies for p53 mutant tumors is that germline
deletion of both alleles of PIP4K2A and one allele of PIP4K2B
in the context of TP53/ results in a viable mouse with a
dramatic reduction in tumor-dependent death compared to
TP53/ mice that are wild-type for PIP4K2A and B. These
results (and studies of the PIP4K2A/, PIP4K2B+/ or
PIP4K2A+/, PIP4K2B/ mice in the context of wild-typeTP53) indicate that normal tissues tolerate well the loss of three
out of four alleles of the PIP4K2A and PIP4K2B genes, but that
tumors are not viable in this context. PI5P4Ka and b are kinases
and pharmaceutical companies have shown that it is possible to
develop highly specific inhibitors of both protein kinases and
lipid kinases. The synthetic lethality that we observe between
TP53 loss and loss of these kinases indicates that drugs that
target either the enzyme PI5P4Kb alone or that target both
PI5P4Ka and b are likely to be well tolerated and very effective
on tumors that have loss of function mutations or deletions of
TP53. Our observations with BT474 cells suggest that HER2-
positive tumors that have amplifications of PIP4K2B and
mutations in TP53 may be particularly sensitive to PI5P4Ka,b
inhibitors.
The ERBB2 (Her2) amplicon on chromosome 17 is variable in
size and can contain a number of cancer-related genes in addi-
tion to the ERBB2 locus (Figure 1A). Clinically, patients who have
tumors with small amplicons confined to the ERBB2 locus have
the greatest benefit from ERBB2-directed therapies such as
Trastuzumab, whereas tumors with wider ERBB2 amplicons
have poor responses, suggesting coamplification of genes that
contribute to Trastuzumab resistance (Morrison et al., 2007).
PIP4K2B may be a candidate for an adjacent coamplified gene
that confers Trastuzumab resistance, and, conversely, concom-
itant inhibition of ERBB2 and PIP4K2B could be a highly effective
treatment option for ERBB2 (Her2)-positive tumors that are p53
mutant and PIP4K2B amplified.
EXPERIMENTAL PROCEDURES
Cell Culture
All cells were incubated in a 37C or 32C humidified incubator with 5% CO2.
All breast cancer cell lines were obtained from ATCC and were cultured in Dul-
becco’s modified Eagle medium (Mediatec). MEFs were cultured in Dul-
becco’smodified Eaglemedium (Mediatech). All themedia was supplemented
with 10% fetal bovine serum (Gemini Bio-Products), 100 U/ml penicillin/strep-
tomycin (Mediatech). Mouse embryonic fibroblasts (MEFs) were isolated from
E13.5 embryos as described previously (Hurov et al., 2001).
Virus Production and Infection
293T packaging cell line was used for lentiviral amplification, and all lentiviral
infections were carried out as previously described (Moffat et al., 2006). In
brief, viruses were collected 48 hr after infection, filtered, and used for
infecting cells in the presence of 8 mg/ml polybrene prior to puromycin selec-
tion. All lentiviral vectors were obtained from Broad Institute TRC shRNA
library. PI5P4Ka pLK0.1 shRNA sequence 1 is TRCN0000006009 and
sequence 2 is TRCN0000006010. PI5P4Kb pLK0.1 shRNA sequence 1 is
TRCN0000006013, and sequence 2 is TRCN0000006017. The pLK0.1 vector
was used as the control. To generate virus using the above-described transfer
vector, we used pMD2.G (Addgene plasmid 12259) and psPAX2 (Addgene
plasmid 12260). Mouse PI5P4Kb (GenBank number BC047282) was cloned
into the pLNCX2 retroviral vector along with a Kozak sequence and a FLAG
tag at the N terminus of the cDNA using in-fusion cloning reagents and the
manufacturer’s cloning protocol (Clontech Laboratories). BT474 were infected
and stable lines were selected with 1 mg/ml of G418 for 2 weeks. Post-G418
selection, knockdown of PI5P4Ka and PI5P4Kb were performed as above.
BT474 cells were selected with 2 mg/ml of puromycin.
Immunoblot Analysis and Antibodies
Total cell lysates were prepared by washing cells with cold phosphate-buff-
ered saline, and then the cells were lysed with buffer containing 20 mM Tris/
HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1% Triton asCell 155, 844–857, November 7, 2013 ª2013 Elsevier Inc. 855
well as protease and phosphatase inhibitors. Protein was measured using the
Bradford assay (Bio-Rad), and at least 50 mg of total cell lysates was run on a
SDS-polyacrylamide gel electrophoresis. The proteins were transferred on to a
nitrocellulose membrane, and membranes were probed overnight at 4C with
the appropriate primary antibody. Antibodies usedwere as follows: PI5P4Ka/b
(Schulze et al., 2006), AKT (Santa Cruz Biotechnology), a-tubulin (Sigma),
GAPDH (Abcam), PI5P4Kb, phosphoAKT-473, phosphoAKT-308, phosphoP-
RAS40, phosphoERK, phospho-p38MAPK, ERK, p38MAPK, INPP4B, and p21
(Cell Signaling Technology). See also Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and five tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.09.057.
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